Should the candidates secure approval and gain interest beyond Britain and the European Union, The drugmaker is looking particularly at entry into the US market, according to its chief financial officer, David Lawrence.

So we're not thinking very carefully about how we can participate us.

I'm going forward so that Zaveri active internal discussion that we're having to think about now the administration's change now that the US has got vaccines, how do we participate in that further out?

Val Nevas is the only French shot close to entering late stage human trials, with Britain due to receive the first doses produced in late September at the earliest.

A deal for 190 million doses has been agreed with the U.

K by 2025 which could be worth up to €1.4 billion.

That's $1.69 billion for Val Niva.

Lawrence says he expects talks with the European Union for a provisional 60 million doses to conclude within the next few months.

Production of those vaccines will take place in Scotland on Lawrence told Reuters on Monday.

They'll think very hard about partnering with different regions if demand goes beyond that facilities capacity, Although he did not say whom the company might team up with, any partnership, might involve both production and access to markets.

Veneva said its provisional Phase three trial plan after April would involve 4000 test subjects across Britain on would likely involve a comparison against a proven vaccine rather than a placebo.